Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares traded lower over the last trading session, losing -1.63% on 02/11/21. The shares fell to a low of $20.87 before closing at $21.06. Intraday shares traded counted 0.19 million, which was 70.96% higher than its 30-day average trading volume of 662.19K. SNDX’s previous close was $21.41 while the outstanding shares total 44.16M. The firm has a beta of 1.79. The stock’s Relative Strength Index (RSI) is 46.68, with weekly volatility at 6.53% and ATR at 1.40. The SNDX stock’s 52-week price range has touched low of $6.88 and a $27.85 high.
Investors have identified the Biotechnology company Syndax Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $987.50 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Syndax Pharmaceuticals Inc. (SNDX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 177.43 million total, with 15.16 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -1.68 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SNDX sounds very interesting.
Is the stock of SNDX attractive?
In related news, Chief Executive Officer, Morrison Briggs sold 35,156 shares of the company’s stock in a transaction that recorded on Feb 08. The sale was performed at an average price of 20.55, for a total value of 722,403. As the sale deal closes, the President and COO, Metzger Michael A now sold 15,000 shares of the company’s stock, valued at 302,799. Also, President and COO, Metzger Michael A sold 15,000 shares of the company’s stock in a deal that was recorded on Dec 01. The shares were price at an average price of 22.97 per share, with a total market value of 344,513. Following this completion of acquisition, the Chief Scientific Officer, Ordentlich Peter now holds 29,972 shares of the company’s stock, valued at 694,121. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
5 out of 7 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Syndax Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the SNDX stock. The 12-month mean consensus price target for the company’s shares has been set at $32.50.